Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic, Hearing Before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, Second Session, December 17, 2020   [open pdf - 2MB]

This is the December 17, 2020 hearing on "The Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic," held before the Committee on Oversight and Reform. Purdue Pharma and the Sackler family have been accused of purposefully targeting "high-volume prescribers to boost sales of OxyContin, ignor[ing] and work[ing] around safeguards intended to reduce prescription opioid misuse, and promot[ing] false narratives about their products to steer patients away from safer alternatives and deflect blame toward people struggling with addiction." Civil lawsuits and bankruptcy cases are mentioned, noting ongoing negotiations for restitution. Representatives from the Sackler family and Purdue Pharma are given the opportunity to present their testimony, stating that while they only had good intentions in the creation of OxyContin, they do recognize the devastating effects it has had on families and communities. In statements by Massachussetts' Attorney General Maura Healey and U.S. Attorney General William Barr, they argue that fines and restitution are not enough to provide justice, and that the settlements and bankruptcy cases simply cover up what was done and do not hold any individuals accountable. They ask for public release of documents proving the case against the Sackler family and Purdue Pharma, and reject the proposal that Purdue Pharma become a public benefit company. Statements, letters, and materials submitted for the record include those of the following: David Sackler, Kathe Sackler, and Craig Landau.

Report Number:
Serial No. 116-130
Public Domain
Retrieved From:
U.S. Government Publishing Office: http://www.gpo.gov/
Media Type:
Help with citations